In routine clinical practice, BRAF/MEK-directed targeted therapy is regularly applied as a frontline therapy of choice in patients with advanced and aggressively growing metastatic melanoma who require immediate disease control, due to its rapid onset of activity and high response rates, even in patients with high lactate dehydrogenase (LDH) levels [11]. The gene discussed is MAP2K7; the disease is metastatic melanoma.